Clinical characteristics of patients with APS divided according to the presence/absence of serum anti-β2GPI peptide IgG immunoreactivity
| Characteristic . | Patients with serum anti-β2GPI peptide Abs . | Patients without serum anti-β2GPI peptide Abs . |
|---|---|---|
| Patients with APS, n | 11 | 16 |
| Primary/secondary | 4/7 | 8/8 |
| Sex, M/F | 2/9 | 4/12 |
| Median age, y (range) | 42 (27-58) | 44 (28-71) |
| Median disease duration, y (range) | 6 (0.5-20) | 7 (0.5-16) |
| Arterial thrombosis, n (%) | 4 (36.4) | 8 (50) |
| Venous thrombosis, n (%) | 4 (36.4) | 7 (43.8) |
| Pregnancy morbidity, n (%) | 6 (54.5) | 8 (50) |
| Anti-β2GPI IgG, n (%) | 5 (45.4) | 8 (50) |
| Anti-cardiolipin + β2GPI IgG, n (%) | 4 (36.4) | 8 (50) |
| Characteristic . | Patients with serum anti-β2GPI peptide Abs . | Patients without serum anti-β2GPI peptide Abs . |
|---|---|---|
| Patients with APS, n | 11 | 16 |
| Primary/secondary | 4/7 | 8/8 |
| Sex, M/F | 2/9 | 4/12 |
| Median age, y (range) | 42 (27-58) | 44 (28-71) |
| Median disease duration, y (range) | 6 (0.5-20) | 7 (0.5-16) |
| Arterial thrombosis, n (%) | 4 (36.4) | 8 (50) |
| Venous thrombosis, n (%) | 4 (36.4) | 7 (43.8) |
| Pregnancy morbidity, n (%) | 6 (54.5) | 8 (50) |
| Anti-β2GPI IgG, n (%) | 5 (45.4) | 8 (50) |
| Anti-cardiolipin + β2GPI IgG, n (%) | 4 (36.4) | 8 (50) |